Lung cancer drug reaches brain tumors better than expected

Osimertinib, a targeted therapy for lung cancer with brain metastases, penetrates brain tissue more effectively than previously thought, according to imaging data. The finding could reshape treatment decisions for thousands of patients and influence how drugmakers design cancer therapies to cross the blood-brain barrier.

Originaltitel: Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study